Deans' stroke musings: Robocath, Rennes University Hospital partner with Philips France to research stroke treatments

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, July 7, 2021

Robocath, Rennes University Hospital partner with Philips France to research stroke treatments

If you know anybody in this, remind them that the only goal in stroke is 100% recovery. NOT SOME FUCKING TYRANNY OF LOW EXPECTATIONS they will try to push on survivors.

Robocath, Rennes University Hospital partner with Philips France to research stroke treatments

Robocath and Rennes University Hospital have announced they are launching a co-development research programme using robotics to improve treatments for stroke patients. With the support of Philips France, this unique programme will be implemented over the next four years.

It will begin with a clinical study into the treatment of carotid artery disease using R-One, the first robotic platform developed by Robocath, which has been on the market since 2019. This first-generation robotic solution was designed to improve the treatment of cardiovascular disease by enhancing physicians’ movements through increased precision. It also helps medical staff to drastically reduce their exposure to X-rays, according to a Robocath press release.

“I am delighted to be launching this scientific research partnership with Robocath and to be working with this passionate team,” said François Eugène, interventional neuroradiologist at Rennes University Hospital (Rennes, France). “Robotics is already successfully used to treat coronary disease in humans, and the benefits of this technology can also be applied to the treatment of certain neurovascular diseases. This is largely because precision of movement is a key factor in treating stroke patients; the use of robotics will increase the success rate of these procedures. I am very excited to get started on the clinical study.”

Following this clinical study, the partnership will become an active research and development (R&D) collaboration aimed at improving and enhancing current and future generations of robotic solutions, based on the synergy between both parties’ skills, and know-how.

“This collaboration proves that there is considerable interest in robotics in the medical sector,” said Robocath CEO Lucien Goffart. “It demonstrates the whole scope of potential applications in a range of specialist vascular fields. The combination of Dr Eugène’s enthusiasm and the support of Philips France is the ideal recipe for the success of this research programme, which will undoubtedly represent a pivotal moment in our company’s history.”